Access granted: CMS greenlights more than 150 participants for chronic care experiment

More than 150 companies and providers were provisionally approved for Medicare's experimental ACCESS model, which will pay fixed rates for chronic care such as diabetes, hypertension, anxiety, and depression. CMS said application volume exceeded expectations and extended the initial April 1 deadline to broaden participation. The program could support digital health adoption in Medicare, but the article does not identify specific winners or financial impact yet.

Analysis

This is a supply-shock in digital health reimbursement, not just a pilot expansion. The key second-order effect is that Medicare validation can compress customer acquisition costs across the sector: once a model is CMS-sanctioned, hospital systems and MA plans have a stronger reason to standardize on approved vendors rather than building in-house point solutions. That benefits scaled platforms with regulatory muscle and distribution, while smaller apps that depend on direct-to-consumer monetization may find their economics worse if they are forced into lower, outcome-linked rates.

GOOGL is the cleaner public-market beneficiary than the headline suggests. The embedded optionality is not the revenue from this model itself, but the reinforcement of Google’s healthcare data/AI stack as a trusted layer for chronic-care workflows, which could lower the perceived risk of future enterprise contracts in life sciences and care management. If the model works, it also increases the value of ambient data collection and device integration, pulling more budget away from standalone app vendors toward infrastructure owners and device ecosystems.

The main risk is that the market extrapolates too quickly from provisional approval to durable reimbursement. ACCESS still has utilization, outcomes, and administrative friction risk; if rates are too tight, providers may cherry-pick easy patients, limiting evidence quality and forcing CMS to tighten eligibility within 6-12 months. Another underappreciated downside is channel conflict: incumbent providers may use the program to price digital vendors aggressively, which could cap venture valuations and slow M&A unless there is clear evidence of reduced total cost of care.

Key Decisions for Investors

• Long GOOGL on a 3-6 month horizon: use dips to add exposure to healthcare-adjacent optionality; the risk/reward is asymmetric because this is a free call on broader adoption of Google-enabled clinical workflows with limited near-term earnings dependence.
• Short a basket of late-stage, standalone digital health apps via public comps or the most valuation-sensitive names if liquidity allows: the reimbursement shift favors scaled, integrated platforms over single-feature apps; target 2-4 quarter downside if ACCESS participants pressure pricing.
• Pair trade: long device/data ecosystem exposure vs. short pure-play care-management software where available; the thesis is that reimbursement will reward measurable outcomes and passive data capture more than front-end engagement layers.
• Avoid chasing private-market re-ratings for chronic-care startups for now; wait 2-3 quarters for evidence on patient retention, margins, and Medicare claims before underwriting durable ARR uplift.
• If ACCESS participation expands again, consider a tactical long on healthcare services/analytics vendors with CMS integration capability, but size modestly because implementation risk is high and the model could be revised within 12 months.